Skip to main content

Table 1 Characteristics of DCIS by surrogate molecular subtypes according to the St Gallen international expert consensus 2011 (n=458)

From: Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study

Ductal carcinoma in situ characteristics

All

Luminal A

Luminal B/HER2-

Luminal B/HER2+

HER2+/ER-

Triple negative

Unclassified

P valueb

P valuec

 

n=458

n=186, (%)

n=33, (%)

n=74, (%)

n=61, (%)

n=27, (%)

n=77, (%)

  

Percentage of all

n=458

(40.6)

(7.2)

(16.2)

(13.3)

(5.9)

(16.8)

  

Percentage of all classified

n=381

(48.8)

(8.7)

(19.4)

(16.0)

(7.1)

-

  

Age mean, years

58.2

59.6

55.2

55.2

58.4

59.2

58.2

  

< 50

121(26.4)

48 (25.8)

12 (36.4)

23 (31.1)

14 (23.0)

8 (29.6)

16 (20.8)

0.38

0.42

50- 65

198 (43.2)

77 (41.4)

14 (42.4)

33 (44.6)

30 (49.2)

7 (25.9)

37 (48.0)

  

> 65

139 (30.3)

61 (32.8)

7 (21.2)

18 (24.3)

17 (27.9)

12 (44.4)

24 (31.2)

  

Detection mode

         

Screening

345 (75.5)

134 (72.0)

27 (81.8)

67 (90.5)

44 (72.1)

18 (66.7)

55 (71.4)

0.10

0.16

Clinically

112 (24.5)

51 (27.4)

6 (18.2)

7 (9.5)

17 (27.9)

9 (33.3)

22 (28.6)

  

Tumor size

         

Unifocal, mean, mm

16.7

14.9

16.5

16.4

21.8

19.9

16.3

0.93d

0.91d

Multifocal (number)

n=54

n=22

n=3

n=11

n=8

n=3

n=7

  

Histopathological grade a

         

Grade 1

37 (8.1)

23 (12.4)

1 (3.0)

1 (1.4)

1 (1.6)

1 (3.7)

10 (13.0)

<0.01

<0.01

Grade 2

203 (44.6)

121 (65.0)

17 (51.5)

20 (27.0)

6 (9.8)

9 (33.3)

32 (41.6)

  

Grade 3

215 (47.3)

42 (22.6)

15 (45.5)

53 (71.6)

54 (88.5)

17 (63.0)

35 (44.4)

  

Type of surgery

         

Breast Conserving Surgery

359 (78.4)

151 (81.2)

28 (84.8)

57 (77.0)

41 (67.2)

22 (81.5)

60 (77.9)

0.17

0.27

Mastectomy

99 (21.6)

35 (18.8)

5 (15.2)

17 (23.0)

20 (32.8)

5 (18.5)

17 (22.1)

  

Postoperative radiotherapy

         

Yes

161 (35.2)

63 (33.9)

17 (51.5)

27 (36.5)

23 (37.7)

9 (33.3)

22 (28.6)

0.42

0.33

No

297 (64.8)

123 (66.1)

16 (48.5)

47 (63.5)

38 (62.3)

18 (66.7)

55 (71.4)

  
  1. aDCIS were classified according to the European Organization for Research and Treatment of Cancer (EORTC) system.
  2. bP-values were calculated between molecular subgroups by IHC, unclassified lesions were excluded.
  3. cP-values were calculated between molecular subgroups by IHC, unclassified lesions were included.
  4. dChi-square test of categorical size groups (unifocal vs. multifocal).